1

1 Widely accessible prognostication using medical history for fetal

2 growth restriction and small for gestational age in nationwide insured

3 women

- 4 Herdiantri SUFRIYANA, MD PhD;^{1,2} Fariska Zata AMANI, MD;³ Aufar Zimamuz
- 5 Zaman AL HAJIRI, MD;⁴ Yu-Wei WU, PhD;^{1,5} Emily Chia-Yu SU, PhD.^{1,5,6, *}
- ⁶ ¹ Graduate Institute of Biomedical Informatics, College of Medical Science and
- 7 Technology, Taipei Medical University, 250 Wu-Xing Street, Taipei 11031, Taiwan
- 8 ² Department of Medical Physiology, Faculty of Medicine, Universitas Nahdlatul
- 9 Ulama Surabaya, 57 Raya Jemursari Road, Surabaya 60237, Indonesia
- ³ Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Nahdlatul
- 11 Ulama Surabaya, 57 Raya Jemursari Road, Surabaya 60237, Indonesia
- ⁴ Faculty of Medicine, Universitas Nahdlatul Ulama Surabaya, 57 Raya Jemursari Road,
- 13 Surabaya 60237, Indonesia
- ⁵ Clinical Big Data Research Center, Taipei Medical University Hospital, 250 Wu-Xing
- 15 Street, Taipei 11031, Taiwan
- ⁶ Research Center for Artificial Intelligence in Medicine, Taipei Medical University,
- 17 250 Wu-Xing Street, Taipei 11031, Taiwan
- 18 * Corresponding author: Graduate Institute of Biomedical Informatics, College of
- 19 Medical Science and Technology, Taipei Medical University, 250 Wu-Xing Street,
- 20 Taipei 11031, Taiwan. Phone: +886-2-66382736 ext. 1515. Email address:
- 21 <u>emilysu@tmu.edu.tw</u>.

22 Abstract

23 **Objectives:** Prevention of fetal growth restriction/small for gestational age is adequate 24 if screening is accurate. Ultrasound and biomarkers can achieve this goal; however, both 25 are often inaccessible. This study aimed to develop, validate, and deploy a prognostic 26 prediction model for screening fetal growth restriction/small for gestational age using 27 only medical history. Methods: From a nationwide health insurance database 28 (n=1,697,452), we retrospectively selected visits of 12-to-55-year-old females to 22,024 29 healthcare providers of primary, secondary, and tertiary care. This study used machine 30 learning (including deep learning) to develop prediction models using 54 medical-31 history predictors. After evaluating model calibration, clinical utility, and explainability, 32 we selected the best by discrimination ability. We also externally validated and 33 compared the models with those from previous studies, which were rigorously selected 34 by a systematic review of Pubmed, Scopus, and Web of Science. **Results:** We selected 35 169,746 subjects with 507,319 visits for predictive modeling. The best prediction model 36 was a deep-insight visible neural network. It had an area under the receiver operating 37 characteristics curve of 0.742 (95% confidence interval 0.734 to 0.750) and a sensitivity 38 of 49.09% (95% confidence interval 47.60% to 50.58% using a threshold with 95% 39 specificity). The model was competitive against the previous models in a systematic 40 review of 30 eligible studies of 381 records, including those using either ultrasound or 41 biomarker measurements. We deployed a web application to apply the model. 42 Conclusions: Our model used only medical history to improve accessibility for fetal 43 growth restriction/small for gestational age screening. However, future studies are 44 warranted to evaluate if this model's usage impacts patient outcomes.

Key words: fetal growth restriction, small for gestational age, machine learning, deeplearning, electronic health records, risk prediction.

47 Introduction

Fetal growth restriction (FGR) and small for gestational age (SGA) are two terms of a 48 49 single condition with the same diagnostic criterion in principle but different measures in practice.¹ This condition is the second leading cause of preventable perinatal deaths.² 50 51 The prevention method depends on FGR/SGA predictions with a clinically acceptable predictive performance.³ However, most settings lack accessibility to predictors in 52 existing prediction models.⁴ 53 A pregnancy with FGR likely results in delivering low-birth-weight infants,⁵ an 54 indirect cause of neonatal deaths.⁶⁻⁸ Neonatal mortality rates varied from 20 to 30 deaths 55 per 1000 live births worldwide in 2013.⁹ Low-birth-weight infants also need to spend 56 time in a neonatal intensive care unit.¹⁰ But, this requires high costs and is a limited 57 resource in many countries.^{11,12} Prevention of FGR/SGA may reduce neonatal mortality 58 and associated costs.¹³ Several preventive strategies were found to be effective for 59 FGR/SGA;¹⁴ yet, this intervention needs a screening method with a good predictive 60 61 performance.³ 62 Since a low-cost method such as symphysis fundal height was not recommended

63 by a Cochrane review, mainly due to low sensitivity (~17%), there is a trend to employ either ultrasound or biomarker measurements for FGR/SGA screening.¹⁵ Nonetheless, 64 these methods are inaccessible in resource-limited settings.^{15,16} Meanwhile, there was an 65 association detected of FGR/SGA with a woman's medical history.¹⁷ Because a health 66 insurance claim database abundantly records medical histories, this allows proactive 67 68 screening for FGR/SGA, particularly in countries with universal health coverage.¹⁸ 69 Screening by medical history is also independent of the number of pregnancy 70 consultations on which FGR detection depends (hazard ratio 1.15, 95% confidence

71	interval [CI] 1.05 to 1.26) 19	Howayar studios have	vot to dovalor	a screening method
/1	11101 var[C1] 1.05 to 1.20).	nowever, studies have	yet to develop	a screening method

- 72 for FGR/SGA using only medical history.
- 73 Prognostic predictions of FGR/SGA using medical histories can be either a
- 74 prediction model for use in resource-limited settings or a preliminary prediction model
- 75 before ordering ultrasound and biomarker measurements. Both statistical and
- 76 computational machine learning can predict pregnancy outcomes in advance,²⁰
- including deep learning and those using only medical history.^{20,21} We aimed to develop,
- validate, and deploy a prognostic prediction model for screening FGR/SGA using only
- 79 medical history in nationwide insured women.

80 Materials and Methods

81 Report completeness of this study was according to the transparent reporting of a

- 82 multivariable prediction model for individual prognosis or diagnosis (TRIPOD)
- 83 checklist (Appendix A).²² We followed a protocol with the same software and hardware
- 84 (Tables B1-B3, C1),²³ except those stated otherwise. This study was under a single
- 85 project that compared a deep-insight visible neural network (DI-VNN) to other machine
- 86 learning algorithms to predict several outcomes in medicine. The Taipei Medical
- 87 University Joint Institutional Review Board exempted this project from the ethical
- 88 review (TMU-JIRB no.: N202106025).

89 Study design and data source

90 We applied a retrospective design to select subjects from a public dataset version 2

- 91 (August 2019;²⁴ access approval no.: 510/PPID/1223) of a nationwide health insurance
- 92 database in Indonesia. The dataset was a cross-sectional, random sampling of ~1% of

5

93	insurance holders within 2 years up to 2016. This sampling included all affiliated
94	healthcare providers ($n=22,024$) at all levels (i.e., primary, secondary, and tertiary care).
95	The inclusion criteria were females aged 12 to 55 years who had visited primary,
96	secondary, or tertiary care facilities. All visits afterward were exprotocolcluded if a
97	woman was pregnant and had a delivery. If a woman became pregnant twice within the
98	dataset period, then different identifiers were assigned to differentiate the pregnancy
99	periods of that woman. To determine a delivery, we used several codes of diagnoses and
100	procedures (Table C2).
101	This study developed a prediction model for detecting in advance a visit by a
102	subject who would be diagnosed with either FGR or SGA. We pursued to achieve an
103	acceptable sensitivity at 95% specificity but using more-accessible predictors.
104	Nevertheless, we compared our prediction models with those from previous studies
105	selected by systematic review methods to evaluate if our predictive modeling was
106	successful. Since there were different policies in choosing a prediction threshold (e.g.,
107	that at 90% vs. 95% specificity), the comparison was conducted using receiver
108	operating characteristics (ROC) curves and the area under the ROC curve (AUROC).
109	The event outcome definition in this study utilized the International
110	Classification of Disease version 10 (ICD-10) codes. These were codes preceded by
111	either O365 (maternal care for known or suspected fetal growth) or P05 (disorders of
112	newborns related to slow fetal growth and fetal malnutrition). Both codes indicating
113	FGR and SGA were assigned with those respectively for mothers and fetuses/newborns.
114	A nonevent outcome was assigned if the end of pregnancy was identified within the
115	dataset period by the codes for determining delivery. Otherwise, we assigned an
116	outcome to a censored one.

6

117	Candidate predictors were only medical histories of diagnoses and procedures.
118	These were either single or multiple ICD-10 codes. As extensively described in the
119	protocol, ²² the preprocessing of candidate predictors consisted of (1) preventing zero
120	variance, perfect separation and leakage of the outcome, and redundant predictors; (2)
121	simulating real-world data; and (3) systematically determining the multiple ICD-10
122	codes for defining latent candidate predictors based on prior knowledge. After this
123	preprocessing (Tables C3-C7), we identified 54 candidate predictors, including four
124	latent candidate predictors of multiple pregnancies, varicella, urinary tract infections,
125	and placenta previa.

126 Statistical analysis

We developed five models using different algorithms and hyperparameter tuning, as 127 described in the protocol.²² The first applied ridge regression (RR). The second to fourth 128 129 models used 54 candidate predictors transformed into principal components (PCs). We 130 applied three algorithms using these PCs: (1) elastic net regression (PC-ENR); (2) 131 random forest (PC-RF); and (3) gradient boosting machine (PC-GBM). The fifth model was a deep-insight visible neural network (DI-VNN). However, unlike the protocol,²² 132 133 we did not limit this model to only 22 of 54 candidate predictors, which had a false 134 discovery rate of \leq 5% based on differential analyses with Benjamini-Hochberg multiple 135 testing corrections. Instead, we used all 54 candidate predictors considering the 136 feasibility of constructing the data-driven network architecture. In addition, all model 137 recalibration was by either a logistic regression or a general additive model using 138 locally weighted scatterplot smoothing. The recalibration procedure also differed from the protocol.²² This is because the models only sometimes resulted in a wide range of 139 140 predicted probabilities, as required for recalibration. Unlike the protocol, we chose 100

7

141	repetitions for bootstrapping, considering the sample size of this study compared to that
142	of the protocol. Details on model development and validation are described in Table B2.
143	For deployment, this model will predict the outcome each time an insured
144	woman visits a healthcare provider. We provided the best model in this study as a web
145	application. A user is only required to upload a comma-separated value (.csv) file
146	consisting a two-column table. It includes column headers of "admission_date" (yyyy-
147	mm-dd) and "code" (ICD-10 code at discharge) from previous to current visits.
148	We computed an uncertainty interval (i.e., 95% confidence interval, CI) for each
149	evaluation metric. This interval inference used subsets of an evaluated set, resampled by
150	bootstrapping and cross-validation. All analytical codes were publicly shared (see "Data
151	sharing statement").
152	The selection of latent candidate predictors in the first model applied inverse
153	probability weighting for the multivariate analyses, according to the protocol. ²² Results
154	were also compared to those by outcome regression. We selected a latent candidate
155	predictor if its association with the outcome had an interval of odds ratio (OR)
156	excluding a value of 1.
157	The evaluation metrics were those for assessing the models' calibration, utility,
158	explainability, and discrimination. To evaluate the model calibration, we assessed (1) a
159	calibration plot with a regression line and histograms of either event or nonevent
160	distribution of the predicted probabilities; (2) the intercept and slope of the linear
161	regression; and (3) the Brier score. We measured the clinical utility using a decision
162	curve analysis by comparing the net benefits of a model with those if we treated all

163 predictions as either positive (i.e., treat all) or negative (i.e., treat none). Clinicians (i.e.,

164 FZA and AZZAH) assessed the explainability. They were given counterfactual

8

165	quantities for each predictor in a model. ²⁵ These consisted of the probability of	
166	necessity (PN; Equation 1) and the probability of sufficiency (PS; Equation 2).	
167	Eventually, we evaluated the discrimination ability of well-calibrated models by the	
168	ROC curve and sensitivity at 95% specificity.	
169	$PN = rac{number of predicted nonevents if changing the predictor to negative}{number of predicted events with a positive predictor}$	Equation 1
170	$PS = \frac{number of predicted events if changing the predictor to positive}{number of predicted nonevents with a negative predictor}$	Equation 2
171	Furthermore, we compared our models with previous ones identified by a	
172	systematic review and meta-analysis (see "Comparison to previous models"). We	
173	compared the best model with those from previous studies. These were identified by	
174	following 11 of 14 items in section methods of the preferred reporting items for	
175	systematic reviews and meta-analyses (PRISMA)-extended checklist statements. ²⁶	
176	Those items are described in Table B4.	
177	Results	

178 Subject characteristics

- 179 From the database (n=1,697,452), we selected 12-to-55-year-old females (n=169,746)
- 180 that had visited (*n*=507,319) primary, secondary, or tertiary care (Figure 1). After
- 181 removing subjects with no pregnancy and their visits, we split the selected data for
- 182 internal and external validation. There were no overlapped visits between the internal
- and external validation sets. We only used the former to develop the prediction models
- 184 in this study, including association tests to select candidate predictors.
- 185

9

186	To characterize subjects in the internal validation set (Table 1), we also included
187	subjects with uncensored outcomes ($n=26,576$). There were differences between
188	subjects without and those with FGR/SGA based on multiple univariate analyses. These
189	were in terms of subject characteristics, i.e.: (1) maternal age; (2) third vs. first
190	categories of the insurance class; (3) single vs. married categories of the marital status;
191	and (4) private company vs. central-government employee categories of the occupation
192	segment of the householder. We also identified differences in terms of latent candidate
193	predictors. Two of these variables were the risk of adverse pregnancy by maternal age
194	and a low socioeconomic status. The former represented maternal age of either <20
195	or >25 years, while the latter represented either the third insurance class or unemployed
196	householder (Table C7). Differences in the latent candidate predictors implied their
197	associations with the outcome.

198

Table 1

199 Association tests

To select latent candidate predictors in the prediction models, their associations with the outcome were verified by multivariate analyses using inverse probability weighting (see Table C8 for comparison to those verified by logistic regression). We adjusted associations using confounders (Table 2; Figures B1-B9). Significant associations persisted after adjustment, in which the effect sizes only slightly changed. However, since the effect sizes were small, the selected latent candidate predictors might be weak predictors for the prediction models.

207

Table 2

208 The best prediction model

209	Only three of the five models were approximately well-calibrated (Figure 2a): the PC-
210	ENR, PC-GBM, and DI-VNN. Among these models, the PC-GBM was considerably
211	the best-calibrated (intercept -0.00098, 95% CI -0.13098 to 0.12902; slope 0.95, 95%
212	CI 0.46 to 1.44; Brier score 0.0063). Nevertheless, the downstream analyses evaluated
213	all of the well-calibrated models.
214	Figure 2
215	The net benefits of these models were higher than those of either the treat-all or
216	treat-none prediction (Figure 2b). It also applied to those using a threshold of 95%
217	specificity. With this threshold, we found the DI-VNN to be the best model in terms of
218	clinical utility with a net benefit of 0.0023 (95% CI 0.0022 to 0.0024).
219	Regarding model explainability, both clinicians chose the DI-VNN among the
220	well-calibrated models. They considered the plausibility of the top-five predictors
221	according to the counterfactual probabilities (Table 3). One of the top predictors in the

222 DI-VNN, i.e., severe preeclampsia, could change most of the predicted events into

nonevents (PN 98.57%, 95% CI 98.5% to 98.63%) if the predictors were changed from

- positive to negative. Most of the nonevents were also changed into events (PS 2.08%,
- 225 95% CI 2.07% to 2.09%) if the predictors were changed from negative to positive. In
- addition, we also show the models' parameters (Tables C9-C14) and all counterfactual
- 227 probabilities (Tables C15-C17).
- 228

Table 3

The discrimination ability differed among the well-calibrated models according
to the ROC curves (Figure 3) and AUROCs (Figure 4). Based on the internal calibration

11

231	split, we identified that the best model was also the DI-VNN (AUROC 0.742, 95% CI
232	0.734 to 0.750; sensitivity 49.09%, 95% CI 47.60% to 50.58%). Using external
233	validation, the AUROC of the DI-VNN (0.561, 95% CI 0.558 to 0.564) was
234	considerably robust (i.e., the 95% CI >0.5).
235	Figure 3
236	Furthermore, we compared the best model with those from previous studies.
237	Only three studies fulfilled the eligibility criteria from three literature databases within
238	the last 5 years. All of the studies were systematic reviews. Thus, we also searched
239	eligible articles in the systematic reviews, including those published more than 5 years
240	earlier. This step resulted in 381 records, including the three systematic reviews (Figure
241	B10). We included 27 studies (Tables D1, D2) of these records for the meta-analysis.
242	These studies used only a training set; thus, the evaluation metrics were extracted only
243	from the training set. We categorized these studies based on the publication year such
244	that the trend of the predictor modalities could be differentiated. By estimation, the DI-
245	VNN was outperformed by those using ultrasound only from previous studies published
246	from 1992 to <2002 (Figures 3, 4, Table C18). This finding was according to the
247	sensitivity. However, those models were developed using smaller sample sizes (Figure 3)
248	and were only evaluated using training sets (Figure 4). We also identified the latter issue
249	for the previous model, which used both ultrasound and biomarkers but without other

250 predictors, from a previous study published in a later year. Meanwhile, based on the

251 AUROC using external validation splits, the DI-VNN was also estimated to outperform

the previous models, which used either ultrasound or biomarkers without or with other

12

253 predictors, from previous studies published from 2002 to 2016 (i.e., the two latest

- 254 groups of publication years).
- 255 Figure 4

Eventually, we chose the DI-VNN to predict FGR/SGA in advance among 12to-15-year-old females that visited primary, secondary, or tertiary care. Similar to the development pipeline of the prediction model, only a pregnant woman was eligible for the use of the DI-VNN to compute a predicted probability of FGR/SGA. We deployed the DI-VNN as a web application (<u>https://predme.app/fgr_sga/</u>). It can be used for future use or independent validation of the DI-VNN because it is open access.

262 Discussion

263 We developed, validated, and deployed a web application to predict FGR/SGA in

advance using the medical history of diagnoses and procedures. The prediction model

265 for the web application was the DI-VNN, chosen among five prediction models in this

study, using only an internal validation set. However, external validation also

267 demonstrated the robustness of the DI-VNN's predictive performance. It was also

comparable to those developed in the previous studies, which used ultrasound and

269 biomarkers without or with other predictors.

270 For predicting FGR/SGA, the previous models, as systematically reviewed in

this study (Table D2), mainly required either ultrasound or biomarker measurements

and a specific range of gestational ages. The models included those which were

273 competitive with the DI-VNN based on the AUROC by internal validation (Figure 4).

274 The models were by Shlossman, et al ²⁷ (nos. 17e, 17f, and 17b), Bednarek, et al ²⁸ (no.

275 21), Valiño, et al ²⁹ (no. 16), and Poon, et al ³⁰ (no. 24). Conversely, external validation

13

276	estimated that the DI-VNN would outperform the other previous models with the
277	similar requirements. The models were by Bano, et al ³¹ (no. 22a), Carbone, et al ³² (no.
278	15c), Leung, et al ³³ (no. 8c), and Krantz, et al ³⁴ (no. 9b). Furthermore, evaluation of
279	the previous models used training sets only, in which the predictive performances might
280	have been overoptimistic.
281	The DI-VNN required neither ultrasound nor biomarkers without or with other
282	predictors. We would expect wider access for FGR/SGA predictions as either (1) a
283	prediction model for use in resource-limited settings or (2) a preliminary prediction
284	model before ordering advanced predictor measurements. However, the DI-VNN needs
285	an impact study to evaluate its effect on patient outcomes in various settings.
286	An effective prevention for FGR was given by ≤ 16 weeks' gestation. ³ To widen
287	prevention time window, more clinical trials are needed. These studies are more
288	efficient if they are conducted among pregnant women with higher risk, as predicted by
289	the DI-VNN. Since it did not require a specific range of gestational ages, the DI-VNN
290	opens more opportunities to conduct such trials.
291	One of the strengths of this study were no requirements from our models,
292	including the DI-VNN, for either ultrasound or biomarker measurements to predict
293	FGR/SGA in advance. We could apply our models to a general population of pregnant
294	women. Furthermore, our model did not require a specific gestational age range for
295	computing the predicted probability. Unlike previous studies, we also conducted
296	external validation to estimate the future predictive performance of the DI-VNN.
297	However, we also identified several limitations of this study. The predictive
298	performance of the best model, i.e., the DI-VNN, was considerably moderate according
299	to the AUROC as was the sensitivity at 95% specificity using an internal validation set.

- 300 However, previous models also achieved similar predictive performances. Another
- 301 limitation was that medical histories from electronic health records might take time to
- 302 execute; yet, this is considerably more achievable in many settings. It still needs to be
- 303 determined if the DI-VNN can improve patient outcomes. Nevertheless, this problem is
- 304 not exclusive to this study because many previous studies in medicine have yet to
- 305 evaluate the impacts of their prediction models.³⁵

306 Abbreviations

- 307 AUROC, area under the receiver operating characteristics curve
- 308 CI, confidence interval
- 309 DI-VNN, deep-insight visible neural network
- 310 ENR, elastic net regression
- 311 FGR, fetal growth restriction
- 312 GBM, gradient boosting machine
- 313 ICD-10, International Classification of Disease version 10
- OR, odds ratio
- 315 PC, principal component
- 316 PN, probability of necessity
- 317 PS, probability of sufficiency
- 318 RF, random forest
- 319 ROC, receiver operating characteristics
- 320 RR, ridge regression
- 321 SGA, small for gestational age

322 Appendices

323 Appendix A

- 324 Transparent reporting of a multivariable prediction model for individual prognosis or
- 325 diagnosis (TRIPOD) checklist.
- 326 Appendix B
- 327 Table B1. Guidelines for developing and reporting machine learning predictive models
- in biomedical research.
- 329 Table B2. Prediction model risk of bias assessment tools (PROBAST).
- 330 Table B3. Clinical checklists for assessing the suitability of machine learning
- applications in healthcare.
- Table B4. Preferred reporting items for systematic reviews and meta-analyses (PRISMA)
- 333 2020 expanded checklist.
- Figure B1. Association diagram of pregnancy-induced hypertension and fetal growth
- 335 restriction (FGR)/small for gestational age (SGA).
- Figure B2. Association diagram of multiple pregnancies and fetal growth restriction
- 337 (FGR)/small for gestational age (SGA).
- 338 Figure B3. Association diagram of malaria and fetal growth restriction (FGR)/small for
- 339 gestational age (SGA).
- 340 Figure B4. Association diagram of varicella and fetal growth restriction (FGR)/small for
- 341 gestational age (SGA).
- 342 Figure B5. Association diagram of risk of an adverse pregnancy by maternal age and
- 343 fetal growth restriction (FGR)/small for gestational age (SGA).
- 344 Figure B6. Association diagram of urinary tract infections and fetal growth restriction
- 345 (FGR)/small for gestational age (SGA).

- 346 Figure B7. Association diagram of placenta previa and fetal growth restriction
- 347 (FGR)/small for gestational age (SGA).
- 348 Figure B8. Association diagram of a low socioeconomic status and fetal growth
- 349 restriction (FGR)/small for gestational age (SGA).
- 350 Figure B9. Unified association diagram and fetal growth restriction (FGR)/small for
- 351 gestational age (SGA).
- 352 Figure B10. Flow diagram to find comparable models from previous studies.

353 Appendix C

- 354 Table C1. R package versions.
- 355 Table C2. Codes for determining delivery or immediate after-delivery care.
- 356 Table C3. Candidate predictors with non-zero variances.
- 357 Table C4. Excluded codes in the training set that may leak outcome information.
- 358 Table C5. Pair-wise Pearson correlations to identify redundant candidate predictors.
- 359 Table C6. Results of systematic human learning and data availability for latent
- 360 candidate predictors.
- 361 Table C7. International classification of disease (ICD)-10 codes or demographical
- 362 variables for latent candidate predictors.
- 363 Table C8. Association tests by logistic regression (LR) and inverse probability
- 364 weighting (IPW).
- 365 Table C9. Principal component (PC) weights.
- 366 Table C10. Principal-component elastic net regression (PC-ENR) weights.
- 367 Table C11. Principal-component gradient boosting machine (PC-GBM) variable
- 368 importance.

- 369 Table C12. Selected predictors based on a differential analysis with a false discovery
- 370 rate (FDR) of <0.05.
- Table C13. Deep-insight visible neural network (DI-VNN) intermediate outputs.
- Table C14. Connections between ontologies under the root of a deep-insight visible
- 373 neural network (DI-VNN).
- Table C15. Probabilities of necessity (PN) and sufficiency (PSs) of predictors in a
- 375 principal-component elastic net regression (PC-ENR).
- 376 Table C16. Probabilities of necessity (PN) and sufficiency (PS) of predictors in a
- 377 principal-component gradient boosting machine (PC-GBM).
- 378 Table C17. Probabilities of necessity (PN) and sufficiency (PS) of predictors in a deep-
- 379 insight visible neural network (DI-VNN).
- 380 Table C18. Extracted data of available evaluation metrics for comparable models.

381 Appendix D

- 382 Table D1. Search and filter results of previous studies.
- 383 Table D2. Comparable models to evaluate the success criteria.

384 Author contributions

- 385 HS: Conceptualization, Methodology, Software, Validation, Formal Analysis,
- 386 Investigation, Data Curation, Writing—Original Draft, Visualization, Project
- 387 Administration, Funding Acquisition. FZA: Validation, Formal Analysis, Data Curation,
- 388 Writing—Review & Editing. AZZAH: Validation, Formal Analysis, Data Curation,
- 389 Writing—Review & Editing. YWW: Conceptualization, Methodology, Writing—
- 390 Review & Editing, Supervision. ECYS: Conceptualization, Methodology, Resources,
- 391 Writing—Review & Editing, Supervision, Funding acquisition. All authors have read
- and approved the manuscript and agreed to be accountable for all aspects of the work in
- 393 ensuring that questions related to the accuracy or integrity of any part of the work are
- appropriately investigated and resolved.

395 **Conflict of interest**

396 The authors report no conflict of interest.

397 Acknowledgments

398 The BPJS Kesehatan in Indonesia permitted access to the sample dataset in this study.

399 This study was funded by: (1) the Postdoctoral Accompanies Research Project from the

400 National Science and Technology Council (NSTC) of Taiwan (grant no.: NSTC111-

401 2811-E-038-003-MY2), and the Lembaga Penelitian dan Pengabdian kepada

402 Masyarakat (LPPM) Universitas Nahdlatul Ulama Surabaya of Indonesia (grant no.:

403 161.4/UNUSA/Adm-LPPM/III/2021) to Herdiantri Sufriyana; and (2) the Ministry of

404 Science and Technology (MOST) of Taiwan (grant nos.: MOST110-2628-E-038-001

and MOST111-2628-E-038-001-MY2), and the Higher Education Sprout Project from

406 the Ministry of Education (MOE) of Taiwan (grant no.: DP2-111-21121-01-A-05) to

407 Emily Chia-Yu Su. These funding bodies had no role in the study design; in the

408 collection, analysis, and interpretation of data; in the writing of the report; or in the

409 decision to submit the article for publication.

410 Data Statements

411 The social security administrator provided the data for health or *badan penyelenggara*

412 *jaminan sosial (BPJS) kesehatan* in Indonesia, with restrictions (access approval no.:

413 510/PPID/1223). Data are available from the authors upon reasonable request and with

414 permission of the BPJS Kesehatan. The latter needs a request to the BPJS Kesehatan for

their sample dataset published in August 2019 via <u>https://e-ppid.bpjs-kesehatan.go.id/</u>.

416 The analytical codes are available at <u>https://github.com/herdiantrisufriyana/fgr_sga</u>.

417 **References**

418	[1]	Fetal growth restriction: Acog practice bulletin, number 227. <i>Obstet Gynecol</i> 2021; 137 :e16-e28.
419		doi: https://doi.org/10.1097/aog.00000000004251.
420	[2]	Nardozza LM, Caetano AC, Zamarian AC, et al. Fetal growth restriction: Current knowledge.
421		Arch Gynecol Obstet 2017;295:1061-77. doi: https://doi.org/10.1007/s00404-017-4341-9.
422	[3]	Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on
423		the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis.
424		Am J Obstet Gynecol 2017;216:110-20.e6. doi: https://doi.org/10.1016/j.ajog.2016.09.076.
425	[4]	Pedroso MA, Palmer KR, Hodges RJ, Costa FDS, Rolnik DL. Uterine artery doppler in
426		screening for preeclampsia and fetal growth restriction. Rev Bras Ginecol Obstet 2018;40:287-
427		93. doi: https://doi.org/10.1055/s-0038-1660777.
428	[5]	Mallia T, Grech A, Hili A, Calleja-Agius J, Pace NP. Genetic determinants of low birth weight.
429		Minerva Ginecol 2017;69:631-43. doi: https://doi.org/10.23736/s0026-4784.17.04050-3.
430	[6]	Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: When? Where? Why? Lancet
431		2005; 365 :891-900. doi: https://doi.org/10.1016/s0140-6736(05)71048-5.
432	[7]	Ausbeck EB, Allman PH, Szychowski JM, Subramaniam A, Katheria A. Neonatal outcomes at
433		extreme prematurity by gestational age versus birth weight in a contemporary cohort. Am J
434		Perinatol 2021;38:880-88. doi: https://doi.org/10.1055/s-0040-1722606.
435	[8]	Tabet M, Flick LH, Xian H, Jen Jen C. Smallness at birth and neonatal death: Reexamining the
436		current indicator using sibling data. Am J Perinatol 2021;38:76-81. doi:
437		https://doi.org/10.1055/s-0039-1694761.

438	[9]	Lehtonen L, Gimeno A, Parra-Llorca A, Vento M. Early neonatal death: A challenge worldwide.
439	[10]	Colalla M. Erárot A. Novois APB. Baud O. Naonatal and long term consequences of fetal
440	[10]	growth restriction Curr Padiatr Ray 2018:14:212-18 doi:
442		https://doi.org/10.2174/1573396314666180712114531
443	[11]	Imran RM Al-Jammali A Neonatal outcomes in a level ii regional neonatal intensive care unit
444	[11]	Pediatr Int 2017: 59 :557-63 doi: https://doi.org/10.1111/ped.13200
445	[12]	Horbar ID Edwards EM Greenberg LT et al Racial segregation and inequality in the neonatal
446	[]	intensive care unit for very low-birth-weight and very preterm infants. JAMA Pediatr
447		2019: 173 :455-61. doi: https://doi.org/10.1001/jamapediatrics.2019.0241.
448	[13]	Ho T, Zupancic JAF, Pursley DM, Dukhovny D. Improving value in neonatal intensive care.
449		Clin Perinatol 2017;44:617-25. doi: https://doi.org/10.1016/j.clp.2017.05.009.
450	[14]	Bettiol A, Avagliano L, Lombardi N, et al. Pharmacological interventions for the prevention of
451		fetal growth restriction: A systematic review and network meta-analysis. Clin Pharmacol Ther
452		2021; 110 :189-99. doi: https://doi.org/10.1002/cpt.2164.
453	[15]	Audette MC, Kingdom JC. Screening for fetal growth restriction and placental insufficiency.
454		Semin Fetal Neonatal Med 2018;23:119-25. doi: https://doi.org/10.1016/j.siny.2017.11.004.
455	[16]	Luntsi G, Ugwu AC, Nkubli FB, Emmanuel R, Ochie K, Nwobi CI. Achieving universal access
456		to obstetric ultrasound in resource constrained settings: A narrative review. Radiography (Lond)
457		2021; 27 :709-15. doi: https://doi.org/10.1016/j.radi.2020.10.010.
458	[17]	Selvaratnam RJ, Wallace EM, Flenady V, Davey MA. Risk factor assessment for fetal growth
459		restriction, are we providing best care? Aust NZJ Obstet Gynaecol 2020;60:470-73. doi:
460		https://doi.org/10.1111/ajo.13147.
461	[18]	Wagstaff A, Neelsen S. A comprehensive assessment of universal health coverage in 111
462		countries: A retrospective observational study. Lancet Glob Health 2020;8:e39-e49. doi:
463	[10]	https://doi.org/10.1016/s2214-109x(19)30463-2.
404	[19]	Andreasen LA, Tabor A, Nørgaard LN, et al. Why we succeed and fail in detecting fetal growth
403		restriction: A population-based study. Acta Obstet Gynecol Scand 2021;100:893-99. doi:
400	[20]	nttps://doi.org/10.1111/aogs.14048.
407	[20]	Surriyana H, Hushayain A, Chen YL, et al. Comparison of multivariable logistic regression and
400		Systematic rayion and mate analysis <i>JMIP Med Inform</i> 2020; 9 :e16502 doi:
409		https://doi.org/10.2196/16503
470	[21]	Sufrivana H. Wu XW. Su EC. Artificial intelligence assisted prediction of preeclampsia:
472	[21]	Development and external validation of a nationwide health insurance dataset of the bris
473		kesebatan in indonesia <i>FRioMedicine</i> 2020: 54 :102710 doi:
474		https://doi.org/10.1016/i.ebiom.2020.102710.
475	[22]	Moons KG. Altman DG. Reitsma JB. et al. Transparent reporting of a multivariable prediction
476	[]	model for individual prognosis or diagnosis (tripod): Explanation and elaboration. Ann Intern
477		<i>Med</i> 2015; 162 :W1-73. doi: https://doi.org/10.7326/m14-0698.
478	[23]	Sufriyana H, Wu YW, Su EC-Y. Human and machine learning pipelines for responsible clinical
479		prediction using high-dimensional data. Protocol Exchange 2021. doi:
480		https://doi.org/10.21203/rs.3.pex-1655/v1.
481	[24]	Ariawan I, Sartono B, Jaya C. Sample dataset of the bpjs kesehatan 2015-2016. Jakarta BPJS
482		Kesehatan; 2019.
483	[25]	Moraffah R, Karami M, Guo R, Raglin A, Liu H. Causal interpretability for machine learning-
484		problems, methods and evaluation. ACM SIGKDD Explorations Newsletter 2020;22:18-33. doi,
485		PMID.
486	[26]	Page MJ, McKenzie JE, Bossuyt PM, et al. The prisma 2020 statement: An updated guideline for
487		reporting systematic reviews. <i>Bmj</i> 2021; 372 :n71. doi: https://doi.org/10.1136/bmj.n71.
488	[27]	Shlossman P, Scisione A, Manley J, Colmorgen G, Weiner S. Doppler assessment of the
489		intratetal vasculature in the identification of intrauterine growth retardation. Which vessel
490 401		is best or is a combination better? American Journal of Obstetrics & Gynecology 1998;178:588.
471 107	[20]	uoi. https://uoi.org/10.1010/J.aj0g.2012.01.022. Padnarak M. Dubial M. Préhorowiaz CH D05.19. Donnlar valocimatry in m1 and m2 accurates
492 103	[20]	of middle cerebral artery in pregnancies complicated by intrautoring growth restriction
495 497		Ultrasound in Obstatrics & Gynacology 2004: 24 :300-01 doi:
495		https://doi.org/https://doi.org/10.1002/uog.1423
		mpon, conorginapon, conorgi 1011002/ cogri 120.

496 497 408	[29]	Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound</i>
490	[30]	Poon I C Karagiannis G Staboulidou I Shafiei A Nicolaides KH Reference range of hirth
500	[50]	weight with gestation and first-trimester prediction of small-for-gestation neonates. <i>Prenat</i>
501		<i>Diagn</i> 2011; 31 :58-65. doi: https://doi.org/10.1002/pd.2520.
502	[31]	Bano S, Chaudhary V, Pande S, Mehta V, Sharma A. Color doppler evaluation of cerebral-
503		umbilical pulsatility ratio and its usefulness in the diagnosis of intrauterine growth retardation
504		and prediction of adverse perinatal outcome. <i>Indian J Radiol Imaging</i> 2010; 20 :20-5. doi:
505		https://doi.org/10.4103/0971-3026.59747.
506	[32]	Carbone JF, Tuuli MG, Bradshaw R, Liebsch J, Odibo AO. Efficiency of first-trimester growth
507		restriction and low pregnancy-associated plasma protein-a in predicting small for gestational age
508		at delivery. <i>Prenat Diagn</i> 2012; 32 :724-9. doi: https://doi.org/10.1002/pd.3891.
509	[33]	Leung TY, Sahota DS, Chan LW, et al. Prediction of birth weight by fetal crown-rump length
510		and maternal serum levels of pregnancy-associated plasma protein-a in the first trimester.
511		<i>Ultrasound Obstet Gynecol</i> 2008; 31 :10-4. doi: https://doi.org/10.1002/uog.5206.
512	[34]	Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human
513		chorionic gonadotropin-beta, pregnancy-associated plasma protein a, and nuchal translucency
514		with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol
515		2004; 191 :1452-8. doi: https://doi.org/10.1016/j.ajog.2004.05.068.
516	[35]	Zhou Q, Chen ZH, Cao YH, Peng S. Clinical impact and quality of randomized controlled trials
517		involving interventions evaluating artificial intelligence prediction tools: A systematic review.
518		NPJ Digit Med 2021;4:154. doi: https://doi.org/10.1038/s41746-021-00524-2.
519		

520 Figure Captions

521 Figure 1. Subject selection by applying a retrospective design and data partitioning

522 for internal and external validations. The set for association tests included censored

- 523 outcomes. The summation of the internal and external validation numbers differs from
- the total because: (1) there were subject overlaps; (2) the numbers of subjects and visits
- in the censored internal validation are not shown; and (3) we excluded subjects with no 526
- 526 pregnancy before data analysis. ^a, the first and second pregnancies of a subject within 527 the database period, not parity; ^b, subjects per pregnancy episode; ^c, only subjects in the
- 528 external random split overlapped with those in the internal validation sets; *n*, sample
- 529 size; (?), number of censoring; (–), number of nonevents; (+), number of events.
- **Figure 2. Model calibration (a) and clinical utility (b).** We evaluated both using a
- calibration split (i.e., ~20% of internal validation set) within the optimal range of
- 532 predicted probabilities (equivalent to thresholds) across all of the models. This figure
- shows only the well-calibrated models. Solid lines with gray shading show the
- regression line and standard errors over point estimates of true probabilities. Dotted lines show a thrachold of 05% specificity. CL confidence interval: DL V/DL does
- 535 lines show a threshold of 95% specificity. CI, confidence interval; DI-VNN, deep-536 insight visible neural network; ENR, elastic net regression; GBM, gradient boosting
- 537 machine; PC, principal component.

538 Figure 3. Model discrimination by receiver operating characteristics (ROC) curves.

539 The evaluation used a calibration split (i.e., ~20% of the internal validation set) for only

- 540 the well-calibrated models. The vertical dotted lines show 95% specificity, while the
- 541 diagonal dotted lines show the area under the ROC curve (AUROC) of 0.5 as a
- 542 reference. DI-VNN, deep-insight visible neural network; ENR, elastic net regression;
- 543 GBM, gradient boosting machine; PC, principal components.

544 Figure 4. Model discrimination by the area under the receiver operating

545 characteristics curves (AUROCs). This figure shows only the well-calibrated models.

- 546 The vertical dotted lines show AUROCs of 0.5 and the averages using internal
- 547 calibration split, training set, and external random and non-random splits. See Appendix
- 548 D for details of eligible models from previous studies. If any predictor list of these
- 549 models is too long, then it is truncated by "...". β hCG, β -subunit human
- choriogonadotropin; BMI, body-mass index; Cig., cigarette; CRL, crown-rump length
- 551 (fetus); CU-R, cerebral-umbilical ratio; DI-VNN, deep-insight visible neural network;
- 552 EFW, estimated fetal weight; ENR, elastic net regression; GBM, gradient boosting
- 553 machine; ICA, internal carotid artery; MCA, middle cerebral artery; NT, nuchal
- translucency thickness (fetus); PAPP-A, pregnancy-associated plasma protein-A; PC,
- 555 principal component; PIGF, placental growth factor; PI, pulsatility index; RA, renal
- artery; RI, resistance index; ROC, receiver operating characteristics; SD, systolic-
- diastolic ratio; sFLT-1, soluble fms-like tyrosinase-1; UA, umbilical artery; UtA,
- terine artery.

Variable		Not FGR/SGA ^a (<i>n</i> =26,459)	FGR/SGA ^a (<i>n</i> =117)	p value
Pregnancy episode	First pregnancy, ^c no. (%)	25,096 (94.85)	109 (93.16)	(reference)
within database period ^b Maternal age	Second pregnancy, ^c no. (%)	1363 (5.15)	8 (6.84)	0.41
	Mean (SD), year	29 (6)	28 (6)	0.006**
Insurance class	First, no. (%)	3604 (13.62)	21 (17.95)	(reference)
	Unspecified, no. (%)	87 (0.33)	1 (0.85)	0.51
	Second, no. (%)	9226 (34.87)	50 (42.74)	0.78
	Third, no. (%)	13,542 (51.18)	45 (38.46)	0.03*
Marital status	Married, no. (%)	16,831 (63.61)	77 (66)	(reference)
	Single, no. (%)	2397 (9.06)	20 (17)	0.02*
	Unspecified, no. (%)	7117 (26.90)	20 (17)	0.05
	Divorced/widowed, no. (%)	114 (0.43)	77 (66)	0.97
Occupation	Central-government employee, no. (%)	7683 (29.04)	20 (17.1)	(reference)
segment of the	Private company employee, no. (%)	9611 (36.32)	57 (48.7)	0.002**
householder	Private company employer or self- employed, no. (%)	7871 (29.75)	35 (29.9)	0.06
	Local-government employee, no. (%)	1278 (4.83)	5 (4.3)	0.42
	Unemployed, no. (%)	16 (0.06)	5 (4.3)	0.98
Pregnancy-induced hypertension	Negative, no. (%)	25,366 (9.6e-01)	98 (8.4e-01)	(reference)
	Positive, no. (%)	1093 (4.1e-02)	19 (1.6e-01)	< 0.001***
Multiple pregnancies	Negative, no. (%)	26,271 (9.9e-01)	112 (9.6e-01)	(reference)
	Positive, no. (%)	188 (7.1e-03)	5 (4.3e-02)	< 0.001***
Malaria	Negative, no. (%)	26,439 (1.0e+00)	117 (1.0e+00)	(reference)
	Positive, no. (%)	20 (7.6e-04)	0 (0.0e+00)	< 0.001***
Varicella	Negative, no. (%)	26,446 (1.0e+00)	117 (1.0e+00)	(reference)
	Positive, no. (%)	13 (4.9e-04)	0 (0.0e+00)	< 0.001***
Risk of adverse	Negative, no. (%)	19,660 (7.4e-01)	93 (7.9e-01)	(reference)
pregnancy by maternal age Urinary tract infection	Positive, no. (%)	6799 (2.6e-01)	24 (2.1e-01)	< 0.001***
	Negative, no. (%)	26,294 (9.9e-01)	116 (9.9e-01)	(reference)
	Positive, no. (%)	165 (6.2e-03)	1 (8.5e-03)	< 0.001***
Placenta previa	Negative, no. (%)	26,187 (9.9e-01)	113 (9.7e-01)	(reference)
	Positive, no. (%)	272 (1.0e-02)	4 (3.4e-02)	< 0.001***
Low	Negative, no. (%)	12,901 (4.9e-01)	72 (6.2e-01)	(reference)
socioeconomic	Positive, no. (%)	13,558 (5.1e-01)	45 (3.8e-01)	0.05*

559 Table 1. Subject characteristics for association tests and internal validation set.

560 561

This table shows only latent candidate predictors with significant associations by multivariate analyses (Table 2). *

 $p \le 0.05$; ** $p \le 0.01$; *** $p \le 0.001$; a, Subject per pregnancy episode (not including censored delivery); b, Not 562 563 564 FGR/SGA vs. FGR/SGA (not including those who were not pregnant); °, The first and second pregnancies of a subject within the database period; FGR, fetal growth restriction; SGA, small for gestational age; SD, standard

deviation.

23

Table 2. Association between each latent candidate predictor and fetal growth restriction (FGR)/small for gestational age (SGA) by inverse probability weighting.

Variable of interest	Unadjusted OR (95% CI; p value)	Adjusted OR (95% CI; p value)	Adjustment
Pregnancy-induced hypertension	1.012 (1.011 to 1.013; <i>p</i> <0.001***)	1.007 (1.007 to 1.008; <i>p</i> <0.001***)	Multiple pregnancies + Risk of adverse
			pregnancy by maternal age
Multiple pregnancies	1.051 (1.047 to 1.054; $p < 0.001^{***}$)	1.048 (1.044 to 1.052; <i>p</i> <0.001***)	Risk of adverse pregnancy by maternal age
Malaria	0.993 (0.993 to 0.993; <i>p</i> <0.001***)	0.993 (0.993 to 0.993; <i>p</i> <0.001***)	Low socioeconomic status
Varicella	0.993 (0.993 to 0.993; p<0.001***)	0.993 (0.993 to 0.993; <i>p</i> <0.001***)	(no adjustment)
Risk of adverse pregnancy by maternal age	0.996 (0.996 to 0.996; <i>p</i> <0.001***)	0.996 (0.996 to 0.996; <i>p</i> <0.001***)	(no adjustment)
Urinary tract infection	1.068 (1.064 to 1.073; <i>p</i> <0.001***)	1.137 (1.128 to 1.146; <i>p</i> <0.001***)	Risk of adverse pregnancy by maternal age
Placenta previa	1.028 (1.026 to 1.031; <i>p</i> <0.001***)	1.022 (1.02 to 1.024; <i>p</i> <0.001***)	Risk of adverse pregnancy by maternal age
Low socioeconomic status	0.999 (0.999 to 1; <i>p</i> =0.05*)	0.999 (0.999 to 1; <i>p</i> =0.05*)	(no adjustment)

567 * $p \le .05$; ** $p \le .01$; *** $P \le .001$; CI, confidence interval; OR, odds ratio.

Table 3. Model explainability by clinical assessments based on counterfactual probabilities.

DI-VNN ^{a, b} M791, Myalgia 97.63% 1.7% Plausible Implausible, only a general symptom 0141, Severe 98.57% 2.08% Implausible Plausible Plausible, especially early-onset preeclampsia (98.5% to 98.63%) (2.07% to 2.09%) Implausible Plausible, especially early-onset 0410, 98.22% 1.34% Plausible Plausible 0410, 98.11% to 98.33%) (1.33% to 1.34%) Plausible Plausible 0470, False labor 98.41% 0.59% Plausible Plausible before 37 (98.15% to 98.67%) (0.59% to 0.59%) Plausible Plausible completed weeks of gestation (98.13% to 98.48%) 0.82% to 0.82%) Plausible Implausible, FGR/SC mostly preterm and term PC-ENR ^b Placenta previa ^c 98.2% 8.39% Implausible Plausible	Model	Top-five predictor	PN (95% CI)	PS (95% CI)	Clinician 1	Clinician 2
97.51% to 97.76%) (1.7% to 1.71%) general symptom 0141, Severe 98.57% 2.08% Implausible Plausible, especially preeclampsia (98.5% to 98.63%) (2.07% to 2.09%) Plausible Plausible Plausible 0410, 98.22% 1.34% Plausible Plausible Plausible 0410, 98.11% to 98.33%) (1.33% to 1.34%) Plausible Plausible 0470, False labor 98.41% 0.59% Plausible Plausible before 37 (98.15% to 98.67%) (0.59% to 0.59%) Plausible Plausible completed weeks of gestation 98.33% 0.82% Plausible Implausible, FGR/SC mostly preterm and term PC-ENR b Placenta previa c 98.2% 8.39% Implausible Plausible	DI-VNN ^{a, b}	M791, Myalgia	97.63%	1.7%	Plausible	Implausible, only a
O141, Severe preeclampsia98.57% (98.5% to 98.63%)2.08% (2.07% to 2.09%)Implausible early-onset preeclampsiaO410, Oligohydramnios O470, False labor before 37 completed weeks of gestation98.11% to 98.33%) (0.59% to 0.59%)1.34% (0.59% to 0.59%)Plausible PlausiblePlausibleO48, Prolonged pregnancy98.33% (98.18% to 98.48%)0.82% (0.82% to 0.82%)PlausibleImplausible, FGR/SC mostly preterm and termPC-ENR bPlacenta previa c98.2%8.39%ImplausiblePlausible			(97.51% to 97.76%)	(1.7% to 1.71%)		general symptom
preeclampsia (98.5% to 98.63%) (2.07% to 2.09%) early-onset preeclampsia O410, 98.22% 1.34% Plausible Plausible Oligohydramnios (98.11% to 98.33%) (1.33% to 1.34%) Plausible Plausible O470, False labor 98.41% 0.59% Plausible Plausible before 37 (98.15% to 98.67%) (0.59% to 0.59%) completed weeks of gestation Implausible, FGR/SC mostly preterm and term O48, Prolonged 98.33% 0.82% Plausible Implausible, FGR/SC mostly preterm and term PC-ENR b Placenta previa c 98.2% 8.39% Implausible Plausible		O141, Severe	98.57%	2.08%	Implausible	Plausible, especially
O410,98.22%1.34%PlausiblePlausibleOligohydramnios(98.11% to 98.33%)(1.33% to 1.34%)PlausiblePlausibleO470, False labor98.41%0.59%PlausiblePlausiblebefore 37(98.15% to 98.67%)(0.59% to 0.59%)PlausiblePlausiblecompleted weeks of gestation98.33%0.82%PlausibleImplausible, FGR/SC mostly preterm and termPC-ENR bPlacenta previa c98.2%8.39%ImplausiblePlausible		preeclampsia	(98.5% to 98.63%)	(2.07% to 2.09%)		early-onset preeclampsia
Oligohydramnios (98.11% to 98.33%) (1.33% to 1.34%) Plausible Plausible 0470, False labor 98.41% 0.59% Plausible Plausible before 37 (98.15% to 98.67%) (0.59% to 0.59%) Plausible Plausible completed weeks of gestation 98.33% 0.82% Plausible Implausible, FGR/SC O48, Prolonged 98.18% to 98.48%) (0.82% to 0.82%) mostly preterm and term PC-ENR b Placenta previa c 98.2% 8.39% Implausible Plausible		O410,	98.22%	1.34%	Plausible	Plausible
O470, False labor before 37 completed weeks of gestation98.41%0.59%PlausiblePlausibleO48, Prolonged 		Oligohydramnios	(98.11% to 98.33%)	(1.33% to 1.34%)		
before 37 (98.15% to 98.67%) (0.59% to 0.59%) completed weeks of gestation (0.59% to 0.59%) (0.59% to 0.59%) O48, Prolonged 98.33% 0.82% Plausible Implausible, FGR/SC mostly preterm and term PC-ENR b Placenta previa c 98.2% 8.39% Implausible Plausible		O470, False labor	98.41%	0.59%	Plausible	Plausible
O48, Prolonged pregnancy98.33%0.82%PlausibleImplausible, FGR/SC mostly preterm and termPC-ENR bPlacenta previa c98.2%8.39%ImplausiblePlausible		before 37 completed weeks of gestation	(98.15% to 98.67%)	(0.59% to 0.59%)		
PC-ENR b Placenta previa c 98.2% 8.39% Implausible		O48. Prolonged	98.33%	0.82%	Plausible	Implausible, FGR/SGA
PC-ENR ^b Placenta previa ^c 98.2% 8.39% Implausible Plausible		pregnancy	(98.18% to 98.48%)	(0.82% to 0.82%)		mostly preterm and term
1	PC-ENR b	Placenta previa ^c	98.2%	8.39%	Implausible	Plausible
(98.15% to 98.25%) (8.39% to 8.39%)		Ĩ	(98.15% to 98.25%)	(8.39% to 8.39%)	1	
E86, Volume 98.08% 8.44% Implausible Plausible		E86, Volume	98.08%	8.44%	Implausible	Plausible
depletion (97.93% to 98.22%) (8.44% to 8.44%)		depletion	(97.93% to 98.22%)	(8.44% to 8.44%)		
K021, Caries of 99.9% 9.31% Implausible Plausible		K021, Caries of	99.9%	9.31%	Implausible	Plausible
dentine (99.88% to 99.91%) (9.3% to 9.32%)		dentine	(99.88% to 99.91%)	(9.3% to 9.32%)		
O410, 98.4% 8.47% Implausible Plausible		O410,	98.4%	8.47%	Implausible	Plausible
Oligohydramnios $(98.32\% \text{ to } 98.49\%)$ $(8.47\% \text{ to } 8.47\%)$		Oligohydramnios	(98.32% to 98.49%)	$(8.4^{\prime}\% \text{ to } 8.4^{\prime}\%)$	T 1 '11	T 1 11 C
U024, Hypertonic, 99.43% $S449$ implausible implausible implausible after supporting the $U0270$ to $U0270$ to $U0270$ to $S449$ to $S449$		0624, Hypertonic,	99.43%	8.44%	Implausible	ECD/SCA onest and
prolonged uterine only during labor		prolonged uterine	(99.37% to 99.49%)	(8.44% to 8.44%)		only during labor
PC-GBM Urinary tract 98.96% 5.7% Implausible Plausible	PC-GBM	Urinary tract	98.96%	5.7%	Implausible	Plausible
infection ^c (98.85% to 99.06%) (5.68% to 5.71%)		infection ^c	(98.85% to 99.06%)	(5.68% to 5.71%)	I	
E282, Polycystic 99.82% 2.34% Implausible Plausible, PCOS		E282, Polycystic	99.82%	2.34%	Implausible	Plausible, PCOS
ovarian syndrome (99.79% to 99.85%) (2.34% to 2.34%) mostly with infertility		ovarian syndrome	(99.79% to 99.85%)	(2.34% to 2.34%)	1	mostly with infertility
which is likely						which is likely
undergoing ovarian						undergoing ovarian
stimulation,						stimulation,
subsequently resultin						subsequently resulting
in twin pregnancy an FGR/SGA						in twin pregnancy and FGR/SGA
E86, Volume 99.08% 16.46% Implausible Plausible		E86, Volume	99.08%	16.46%	Implausible	Plausible
depletion $(98.9\% \text{ to } 99.19\%)$ $(16.43\% \text{ to } 16.49\%)$		depletion	(98.97% to 99.19%)	(16.43% to 16.49%)	T 1 '11	T 1 11 1 1
N832, Other and 98.68% \times 22% implausible implausible only large the second s		N832, Other and	98.68%	8.22%	Implausible	Implausible, only large-
unspecified ovarian (98.51% to 98.80%) (8.2% to 8.24%) size cysts compete w		unspecified ovarian	(98.51% 10 98.80%)	(8.2% 10 8.24%)		fetal growth vet
unspecified cysts are		Cysts				unspecified cysts are
likely small. corrus-						likely small, corpus-
luteum cvsts						luteum cysts
Z349, Supervision 98.65% 1.76% Implausible Implausible, no risk of		Z349, Supervision	98.65%	1.76%	Implausible	Implausible, no risk of
of normal (98.61% to 98.7%) (1.76% to 1.77%) FGR/SGA in normal		of normal	(98.61% to 98.7%)	(1.76% to 1.77%)	-	FGR/SGA in normal
pregnancy, pregnancy unspecified		pregnancy, unspecified		,		pregnancy

The clinicians assessed only the well-calibrated models without information on the predictive performances; the topfive predictors had either a top probability of necessity (PN) or probability of sufficiency (PS); ^a, chosen by clinician 1; ^b, chosen by clinician 2; ^c, latent predictor (see Table 2). CI, confidence interval; DI-VNN, deep-insight visible neural network; ENR, elastic net regression; FGR, fetal growth restriction; GBM, gradient boosting machine; PC, principal component; PCOS, polycystic ovarian syndrome; PN, probability of necessity (probability of predicted outcomes would have been nonevents among samples with a positive predictor and an event if changing the predictor to negative); PS, probability of sufficiency (probability of predicted outcomes would have been events among samples with a negative predictor and a nonevent if changing the predictor to positive); SGA, small for gestational age.







